AtriCure, Inc. officer Salvatore Privitera filed a Form 144 notice on November 4, 2026, disclosing a proposed sale of 8,404 shares of AtriCure common stock on NASDAQ under Rule 144 of the Securities Act of 1933.

Key Highlights

  • Proposed sale: Salvatore Privitera, an officer of AtriCure, Inc., intends to sell 8,404 shares of common stock with an aggregate market value of $546,260.00.
  • Shares outstanding: According to the filing, there are 50,922,283 shares of AtriCure common stock outstanding.
  • Acquisition date: The 8,404 shares were acquired on July 24, 2021, as restricted stock from the issuer.
  • Broker: The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
  • 10b5-1 plan: The filing indicates a Rule 10b5-1 plan adoption date of February 20, 2026.
  • Recent sales: Privitera sold 4,519 shares on September 23, 2026 for $271,140.00; 3,657 shares on September 8, 2026 for $201,135.00; and 7,763 shares on September 2, 2026 for $407,557.50, all within the past three months.

AtriCure Officer Privitera Proposes Rule 144 Sale of Restricted Stock Acquired in 2021

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission on November 4, 2026, Salvatore Privitera, identified as an officer of AtriCure, Inc. (NASDAQ:ATRC), proposes to sell 8,404 shares of the company's common stock. The filing lists an approximate sale date of November 4, 2026, and an aggregate market value of $546,260.00 for the shares to be sold.

The filing discloses that the 8,404 shares were acquired on July 24, 2021, through a restricted stock transaction from the issuer, with payment described as "Not Applicable." The proposed sale is to be conducted on the NASDAQ exchange through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing further notes that the sale is being made in reliance on a Rule 10b5-1 plan adopted on February 20, 2026.

As required by Form 144, Privitera also disclosed three sales of AtriCure common stock during the prior three months: 4,519 shares sold on September 23, 2026 for gross proceeds of $271,140.00; 3,657 shares sold on September 8, 2026 for gross proceeds of $201,135.00; and 7,763 shares sold on September 2, 2026 for gross proceeds of $407,557.50. All three prior sales listed Privitera's address as 7555 Innovation Way, Mason, OH 45040, which is also the address of AtriCure, Inc.

What Was Disclosed

AtriCure officer Salvatore Privitera filed a Form 144 notice proposing the sale of 8,404 restricted shares of AtriCure common stock, valued at $546,260.00, through a broker on NASDAQ, under a Rule 10b5-1 plan adopted February 20, 2026.